|
|
| Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
| Bank Loan Ratings | 6.50 | ACUITE D | Reaffirmed | Issuer not co-operating* | - |
| Total Outstanding | 6.50 | - | - |
|
Rating Rationale |
|
Acuité has reaffirmed the long-term rating of ‘ACUITE D’ (read as ACUITE D) on the Rs.6.50 crore bank facilities of Sreeven Pharma Private Limited (SPPL). The rating continues to be flagged as “Issuer Not Cooperating” and is based on the best available information.
|
| About the Company |
|
Sreeven Pharma Private Limited, a Hyderabad-based company was established in 2003 by Mr. Devendrappa J K. The company, a bulk drug manufacturer plans to enter into manufacturing of pharmaceuticals formulations (tablets, liquid orals, ointments etc.) by setting up a WHO & cGMP (Current Good Manufacturing Practices) certified facility.
|
| Unsupported Rating |
| Not Applicable |
| Non-cooperation by the issuer/borrower: |
|
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date.
Acuité believes that information risk is a critical component in such ratings, and non-cooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies. |
| Limitation regarding information availability: |
|
The rating is based on information available from sources other than the issuer / borrower (in the absence of information provided by the issuer / borrower). Acuité endeavoured to gather information about the entity / industry from the public domain. Therefore, Acuité cautions lenders and investors regarding theuse of such information, on which theindicativecredit rating is based.
|
| Rating Sensitivity |
| No information provided by the issuer / available for Acuite to comment upon. |
| All Covenants |
| Not Applicable |
| Liquidity Position |
| "No information provided by the issuer / available for Acuite to comment upon". |
| Outlook |
| Not Applicable |
| Other Factors affecting Rating |
| Not Applicable |
| Particulars | Unit | FY 23 (Actual) | FY 22 (Actual) |
| Operating Income | Rs. Cr. | 0.05 | 4.32 |
| PAT | Rs. Cr. | (1.11) | (0.92) |
| PAT Margin | (%) | (2278.81) | (21.28) |
| Total Debt/Tangible Net Worth | Times | (7.56) | (51.89) |
| PBDIT/Interest | Times | (3.44) | (0.76) |
| Status of non-cooperation with previous CRA |
| Not Applicable |
| Any other information |
| None |
| Applicable Criteria |
|
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
| Note on Complexity Levels of the Rated Instrument |
|
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’ s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in.
|
|
| |
|
|
||||||||||||||||||||||||||||||||||||
|
|
Contacts |
|
|
|
About Acuité Ratings & Research |
